The merger with Nordic Health Economics AB will guide clients through the Nordic reimbursement landscape
Friedrichsdorf, GERMANY / Gothenburg, Sweden, June 12th 2017: As of 30th May, 2017, the PharmaLex Group, a leading specialist provider of development consulting and scientific affairs, regulatory affairs, quality & compliance and pharmacovigilance, has completed the merger with Nordic Health Economics AB.
Nordic Health Economics (NHE) was founded in 2003 by Ingela Björholt, PhD. NHE experts offer an array of scientific grade services in prospective and retrospective health economics and outcomes research services. These services complement the extensive PharmaLex service portfolio in the Nordic region. NHE works with pharmaceutical companies to guide them through the Nordic reimbursement landscape. The authorities place high demands on the health-economic documentation of products, and NHE’s integration with PharmaLex will ensure that these will be identified in the early strategy and gap analyses of new products. Early alignment with authorities provides a fast and smooth path to reimbursement.
“This merger is an important step to further expand our services in the Nordic region which represents an important pharma market”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. Dr. Tilo Netzer, CEO PharmaLex, added, “Nordic Health Economics (NHE) will strengthen our Nordic footprint by adding an office in Sweden, as well as a new service, namely health economics for the Nordic region.” “We are excited to be joining the PharmaLex Group” said Ingela Björholt, Managing Director, Nordic Health Economics AB. “We are confident that our core services will complement the existing PharmaLex portfolio”, she added.
The PharmaLex Group now has over 650 employees, with 25 offices in 13 countries and more than 600 satisfied clients worldwide.
About PharmaLex <Confidence beyond compliance>:
PharmaLex combines local expertise with global reach in the area of development consulting and scientific services, regulatory affairs and pharmacovigilance. A proven track record of success in outsourcing programs, more than 25,000 successfully completed projects for over 650 clients worldwide, as well as extensive experience in all therapeutic areas and product groups, including advanced therapy medicinal products and biopharmaceuticals, medical and borderline products and alternative therapeutic approaches.
For further information, please contact:
Ms. Eva Keck
Director Business Development Operations, PharmaLex GmbH
+49 621 18 15 38 158
Harrlachweg 6; 68163 Mannheim, Germany